KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Raw Materials (2016 - 2025)

Boston Scientific's Raw Materials history spans 17 years, with the latest figure at $849.0 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 3.66% year-over-year to $849.0 million; the TTM value through Dec 2025 reached $849.0 million, up 3.66%, while the annual FY2025 figure was $849.0 million, 3.66% up from the prior year.
  • Raw Materials for Q4 2025 was $849.0 million at Boston Scientific, roughly flat from $849.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $860.0 million in Q3 2024 and bottomed at $366.0 million in Q1 2021.
  • The 5-year median for Raw Materials is $727.5 million (2023), against an average of $666.8 million.
  • The largest annual shift saw Raw Materials fell 21.99% in 2021 before it skyrocketed 41.09% in 2023.
  • A 5-year view of Raw Materials shows it stood at $452.0 million in 2021, then increased by 21.24% to $548.0 million in 2022, then surged by 41.06% to $773.0 million in 2023, then grew by 5.95% to $819.0 million in 2024, then increased by 3.66% to $849.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Raw Materials are $849.0 million (Q4 2025), $849.0 million (Q3 2025), and $835.0 million (Q2 2025).